Monitoring disease activity in antineutrophil antibody‐associated vasculitis

Abstract

AbstractAntineutrophil cytoplasm antibody (ANCA)–associated vasculitis (AAV) comprises a group of multisystem disorders with alternating periods of relapse and remission. Beyond that, a smouldering progress during apparently clinically silent phases often develops. AAVs are subgrouped in microscopic polyangiitis (MPA), granulomatosis with polyangiitis (GPA), eosinophilic granulomatosis with polyangiitis (EGPA) and renal limited vasculitis (RLV). ANCA are hallmark of this disease entity, although they are not always present. Despite the simplification of treatment, fundamental aspects concerning assessment of its efficacy and its adaptation to encountered complications or to the relapsing/remitting/subclinical disease course remain still unknown. Through the advances in pathogenesis and pathophysiology of AAV a reliable biomarker‐based monitoring and treatment algorithm has not been established and disease management follows not infrequently a “trial and error” approach. Here, we overviewed the most interesting biomarkers reported so far.